OBJECTIVE: This study was designed to detect the expression of bcl-2 and p53 proteins in colorectal carcinomas and to determine their association with the patient survival and stage of the diseases. METHODS: Immunohistochemistry method was used to detect the expression of bcl-2 and p53 proteins in 93 cases of colorectal carcinoma. The stain results were obtained by analyzing the clinic-pathological characteristics of patients. RESULTS: Fifty-seven percent (53/93) of the colorectal carcinomas were bcl-2 protein positive. The positive rate of bcl-2 protein in lymph node involvement cases was lower (15/37) than the cases without node involvement (38/58, P<0.01). The positive rate of p53 protein was 43% (40/93) in colon-rectum carcinomas. No significant correlation was observed between p53 protein expression and clinic-pathological manifestations (P>0.05) but the survival was significantly worse (P=0.0001) in the p53 protein positive cases. Neither bcl-2 nor p53 alone was correlated with stage of the disease. When combined bcl-2/p53 status was analyzed, a group with bcl-2(+) and p53(-) had the best prognosis. This group was significantly associated with earlier Dukes' stages (P=0.1763). In multivariate Cox regression analysis, lymph node involvement and p53 protein expression were two independent factors correlated with survival time. CONCLUSION: The expression of bcl-2 and p53 represent biological characteristics of colorectal carcinomas. Assessment of both bcl-2 and p53 status may be valuable in predicting the prognosis of patients.
OBJECTIVE: This study was designed to detect the expression of bcl-2 and p53 proteins in colorectal carcinomas and to determine their association with the patient survival and stage of the diseases. METHODS: Immunohistochemistry method was used to detect the expression of bcl-2 and p53 proteins in 93 cases of colorectal carcinoma. The stain results were obtained by analyzing the clinic-pathological characteristics of patients. RESULTS: Fifty-seven percent (53/93) of the colorectal carcinomas were bcl-2 protein positive. The positive rate of bcl-2 protein in lymph node involvement cases was lower (15/37) than the cases without node involvement (38/58, P<0.01). The positive rate of p53 protein was 43% (40/93) in colon-rectum carcinomas. No significant correlation was observed between p53 protein expression and clinic-pathological manifestations (P>0.05) but the survival was significantly worse (P=0.0001) in the p53 protein positive cases. Neither bcl-2 nor p53 alone was correlated with stage of the disease. When combined bcl-2/p53 status was analyzed, a group with bcl-2(+) and p53(-) had the best prognosis. This group was significantly associated with earlier Dukes' stages (P=0.1763). In multivariate Cox regression analysis, lymph node involvement and p53 protein expression were two independent factors correlated with survival time. CONCLUSION: The expression of bcl-2 and p53 represent biological characteristics of colorectal carcinomas. Assessment of both bcl-2 and p53 status may be valuable in predicting the prognosis of patients.
Authors: U Manne; R B Myers; C Moron; R B Poczatek; S Dillard; H Weiss; D Brown; S Srivastava; W E Grizzle Journal: Int J Cancer Date: 1997-06-20 Impact factor: 7.396
Authors: L Kaklamanis; A Savage; N Mortensen; P Tsiotos; I Doussis-Anagnostopoulou; S Biddolph; R Whitehouse; A L Harris; K C Gatter Journal: J Pathol Date: 1996-05 Impact factor: 7.996
Authors: Jantine L Westra; Michael Schaapveld; Harry Hollema; Jelle P de Boer; Marian M J Kraak; Debora de Jong; Arja ter Elst; Nanno H Mulder; Charles H C M Buys; Robert M W Hofstra; John T M Plukker Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: G B Baretton; J Diebold; G Christoforis; M Vogt; C Müller; K Dopfer; K Schneiderbanger; M Schmidt; U Löhrs Journal: Cancer Date: 1996-01-15 Impact factor: 6.860
Authors: G Flamini; G Curigliano; C Ratto; A Astone; G Ferretti; P Nucera; L Sofo; A Sgambato; A Boninsegna; F Crucitti; A Cittadini Journal: Eur J Cancer Date: 1996-05 Impact factor: 9.162
Authors: Eliane C M Zeestraten; Anne Benard; Marlies S Reimers; Philip C Schouten; Gerrit J Liefers; Cornelis J H van de Velde; Peter J K Kuppen Journal: Biomark Cancer Date: 2013-07-04